| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach |
| 10 Nov 2026 |
8-K: Regulation FD Disclosure
CORPORATE R&D AND KOL EVENT ACRIVON’S NEW I&I PROGRAMS DIFFERENTIATED ASSETS IDENTIFIED WITH PROPRIETARY AP3 PLATFORM NOVEMBER 10, 2026 Exhibit 99.1 |
| 06 Nov 2026 |
8-K: Other Events
Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 |
| 17 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve... |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms in second half 2026 |
| 19 Mar 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) |
| 02 Mar 2026 |
8-K: Termination of a Material Definitive Agreement
On February 18, 2026, Acrivon Therapeutics, Inc. (the “Company”) announced the completion and certification of its internally, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA) certified laboratory, located on pr... |
| 27 Feb 2026 |
8-K: Regulation FD Disclosure
KOL PANEL DISCUSSION ACR-368 ENDOMETRIAL CANCER TRIAL February 27, 2026 Exhibit 99.1 |
| 08 Jan 2026 |
8-K: Regulation FD Disclosure
ACR-368 AND ACR-2316 CLINICAL DATA AND AP3 PIPELINE UPDATES ACRIVON CONFERENCE CALL January 8, 2026 |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11 |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer |
| 05 Sep 2025 |
8-K: Regulation FD Disclosure
ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) NEXT GENERATION PRECISION MEDICINE CORPORATE PRESENTATION SEPTEMBER 2025 Exhibit 99.1 |
| 13 Aug 2025 |
8-K: Results of Operations and Financial Condition
Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predi... |
| 13 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 13, 2025, Acrivon Therapeutics, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, a quorum of 29,659,010 shares of the Company’s common stock, or 94.59% of the outsta... |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy |
| 07 Apr 2025 |
8-K: Regulation FD Disclosure
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer |
| 27 Mar 2025 |
8-K: Regulation FD Disclosure
Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects |
| 25 Mar 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Forward-looking statements Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or fi... |
| 14 Mar 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
As you know, you are currently performing services for Acrivon Therapeutics Inc. (the “Company”) pursuant to the terms of an offer letter effective June 23, 2023, as amended by the offer letter amendment, dated March 11, 2024 (together, ... |
Loading...